Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1993 Feb 13;306(6875):409–410. doi: 10.1136/bmj.306.6875.409

Screening for hypertrophic cardiomyopathy.

A L Clark, A J Coats
PMCID: PMC1676509  PMID: 8461717

Full text

PDF
409

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark C. E., Henry W. L., Epstein S. E. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med. 1973 Oct 4;289(14):709–714. doi: 10.1056/NEJM197310042891402. [DOI] [PubMed] [Google Scholar]
  2. Codd M. B., Sugrue D. D., Gersh B. J., Melton L. J., 3rd Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989 Sep;80(3):564–572. doi: 10.1161/01.cir.80.3.564. [DOI] [PubMed] [Google Scholar]
  3. Epstein N. D., Fananapazir L., Lin H. J., Mulvihill J., White R., Lalouel J. M., Lifton R. P., Nienhuis A. W., Leppert M. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation. 1992 Feb;85(2):635–647. doi: 10.1161/01.cir.85.2.635. [DOI] [PubMed] [Google Scholar]
  4. Fananapazir L., Chang A. C., Epstein S. E., McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. 1992 Sep;86(3):730–740. doi: 10.1161/01.cir.86.3.730. [DOI] [PubMed] [Google Scholar]
  5. Fananapazir L., Leon M. B., Bonow R. O., Tracy C. M., Cannon R. O., 3rd, Epstein S. E. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 1991 Jan 15;67(2):169–174. doi: 10.1016/0002-9149(91)90440-v. [DOI] [PubMed] [Google Scholar]
  6. Greaves S. C., Roche A. H., Neutze J. M., Whitlock R. M., Veale A. M. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J. 1987 Sep;58(3):259–266. doi: 10.1136/hrt.58.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lewis J. F., Spirito P., Pelliccia A., Maron B. J. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. Br Heart J. 1992 Sep;68(3):296–300. doi: 10.1136/hrt.68.9.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Maron B. J., Gaffney F. A., Jeresaty R. M., McKenna W. J., Miller W. W. Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol. 1985 Dec;6(6):1215–1217. doi: 10.1016/s0735-1097(85)80203-5. [DOI] [PubMed] [Google Scholar]
  9. Maron B. J., Roberts W. C., McAllister H. A., Rosing D. R., Epstein S. E. Sudden death in young athletes. Circulation. 1980 Aug;62(2):218–229. doi: 10.1161/01.cir.62.2.218. [DOI] [PubMed] [Google Scholar]
  10. Maron B. J., Spirito P., Wesley Y., Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986 Sep 4;315(10):610–614. doi: 10.1056/NEJM198609043151003. [DOI] [PubMed] [Google Scholar]
  11. McKenna W. J., Franklin R. C., Nihoyannopoulos P., Robinson K. C., Deanfield J. E. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988 Jan;11(1):147–153. doi: 10.1016/0735-1097(88)90181-7. [DOI] [PubMed] [Google Scholar]
  12. McKenna W. J., Oakley C. M., Krikler D. M., Goodwin J. F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985 Apr;53(4):412–416. doi: 10.1136/hrt.53.4.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McKenna W., Deanfield J., Faruqui A., England D., Oakley C., Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981 Mar;47(3):532–538. doi: 10.1016/0002-9149(81)90535-x. [DOI] [PubMed] [Google Scholar]
  14. Romeo F., Pelliccia F., Cristofani R., Martuscelli E., Reale A. Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J. 1990 Mar;11(3):233–240. doi: 10.1093/oxfordjournals.eurheartj.a059689. [DOI] [PubMed] [Google Scholar]
  15. Rosenzweig A., Watkins H., Hwang D. S., Miri M., McKenna W., Traill T. A., Seidman J. G., Seidman C. E. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991 Dec 19;325(25):1753–1760. doi: 10.1056/NEJM199112193252501. [DOI] [PubMed] [Google Scholar]
  16. Watkins H., Rosenzweig A., Hwang D. S., Levi T., McKenna W., Seidman C. E., Seidman J. G. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992 Apr 23;326(17):1108–1114. doi: 10.1056/NEJM199204233261703. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES